Search

Displaying results 3961 - 3970 of 5302 in total
  1. Drug

    Recombinant Bacterial ACE2 Receptors-like Enzyme

    go.drugbank.com/drugs/DB15741
    Investigational

    ._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.

  2. Drug

    Ligandrol

    go.drugbank.com/drugs/DB13934
    Investigational

    Ligandrol is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis.

  3. Drug

    MaaT013

    go.drugbank.com/drugs/DB18648
    Investigational

    MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.

  4. Drug

    S64315

    go.drugbank.com/drugs/DB17559
    Investigational

    S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Myeloid cell leukemia 1 (Mcl-1).[A257311]

  5. Drug

    IMT504

    go.drugbank.com/drugs/DB17792
    Investigational

    IMT504, a non-CpG 24-mer oligodeoxynucleotide, is an immunomodulatory oligonucleotide currently being investigated as a rabies vaccine.[A259467]

  6. Drug

    Aloglutamol

    go.drugbank.com/drugs/DB13650
    Investigational

    Aloglutamol is an antacid salt of aluminium, gluconic acid, and tris. Proprietary names include Altris, Pyreses, Tasto and Sabro.

  7. Drug

    Pexelizumab

    go.drugbank.com/drugs/DB04949
    Investigational

    Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.

  8. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  9. Drug

    PHE885

    go.drugbank.com/drugs/DB18123
    Investigational

    PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.

  10. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]